A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study


1 Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, D-23538 Lübeck, Germany; 2 German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany; 3 Ordensklinikum Linz Elisabethinen, Linz, Austria; 4 Kliniken für Elektrophysiologie/Rhythmologie,

* Corresponding authors. Tel: +49 451 500 44511, Fax: +49 451 500 44585, Email: tilz6@hotmail.com (R.R.T.); Tel: +49 451 500 75293, Fax: +49 451 500 44585, Email: christian.heeger@gmx.net (C.H.H.)
† The first and last two authors contributed equally to the study.

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. Data on its incidence, management, and outcome are sparse.

Methods and results

This international multicentre registry investigates the characteristics of oesophageal fistulae after treatment of atrial fibrillation by catheter ablation. A total of 553,729 catheter ablation procedures (radiofrequency: 62.9%, cryoballoon: 36.2%, other modalities: 0.9%) were performed, at 214 centres in 35 countries. In 78 centres 138 patients (0.025%, radiofrequency: 0.038%, cryoballoon: 0.0015% ([P < 0.0001]) were diagnosed with an oesophageal fistula. Peri-procedural data were available for 118 patients (85.5%). Following catheter ablation, the median time to symptoms and the median time to diagnosis were 18 (7.75, 25; range: 0–60) days and 21 (15, 29.5; range: 2–63) days, respectively. The median time from symptom onset to oesophageal fistula diagnosis was 3 (1, 9; range: 0–42) days. The most common initial symptom was fever (59.3%). The diagnosis was established by chest computed tomography in 80.2% of patients. Oesophageal surgery was performed in 47.4% and direct endoscopic treatment in 19.8% and conservative treatment in 32.8% of patients. The overall mortality was 65.8%. Mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared to conservative management (89.5%) (odds ratio 7.463 (2.414, 23.072) P < 0.001).

Conclusion

Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high.
Structured Graphical Abstract

**Key Question**
Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. The POTTER-AF study aimed to investigate the characteristics of oesophageal fistulae following catheter ablation in a large multinational registry.

**Key Finding**
Oesophageal fistula after catheter ablation of atrial fibrillation was rare (incidence: 0.025%) and occurred mostly with the use of radiofrequency energy (0.038%) rather than cryoenergy (0.0015%, \(p<0.0001\)). The mortality without surgical or endoscopic intervention was exceedingly high (89.5%).

**Take Home Message**
Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high.

---

**Introduction**
Invasive treatment of atrial fibrillation (AF) by catheter ablation based pulmonary vein isolation (PVI) is being increasingly performed worldwide. Catheter ablation has shown high procedural and long-term follow-up success rates for treatment of paroxysmal and persistent AF.\(^1\) In general, the rate of severe peri- and post-procedural complications is low, and several technical improvements, novel technologies, and energy sources have increased the safety profile of this treatment strategy. However, oesophageal fistula (OF) is a devastating and potentially lethal complication of AF ablation procedures. Its incidence is known to be low and has been reported to range between 0.02% and 0.1% of cases, with a high mortality of 50% to 83%.\(^2,5\) Since OF is a rare complication, only limited information based on case reports, case series, and nationwide registries with a limited number of patients on its incidence, management, and outcome is available in the recent literature.\(^2,3,6–12\) The largest survey to date was conducted in 2015 and included 33 patients with OF after AF ablation.\(^3\) Meanwhile, the total number of AF ablation procedures has significantly increased. Additionally, AF ablation technologies have rapidly changed with increasing numbers of cryoballoon ablations, contact force guidance, and high-power short-duration based radiofrequency (RF) ablations.\(^13–15\) The aim of this worldwide study was to evaluate the incidence, management, and outcome of OF after catheter ablation procedures for AF or atrial tachycardia (AT) treatment.
Methods

Study design

The PrOgnosis following oesophageal fistula formation in patients undergoing catheter ablation for AF (POTTER-AF) study was designed as an international, multi-centre, anonymized registry study to evaluate the incidence, management and outcomes of post-procedural OF after catheter ablation of AF. The survey was conducted at the Department of Rhythmology at the Lübeck University Heart Center under the auspices of the Working Group of Cardiac Electrophysiology of the German Cardiac Society (AGEP, DGK). Experienced electrophysiological centres from all around the world were invited to participate. The registry was approved by the local ethical review board of the University of Lübeck, Germany (AZ 21–291). Each participating centre was responsible for its ethics approval by the local ethics committee. The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. All patient information was anonymized. The POTTER-AF study has been registered at clinicaltrials.gov (NCT05273645). Each participating centre provided data on the total number of patients treated with catheter ablation for AF or AT. Additionally, patients’ baseline characteristics, peri-procedural characteristics, and follow-up data were assessed for patients of AF according to a standardized and uniform online questionnaire survey (SurveyMonkey). Data acquired via SurveyMonkey were assessed for an individual patient level and used for further analysis. The inclusion criteria were patients with an OF (which included atrio-OE, oesophageo-pericardial fistula, or oesophageal perforation) after catheter ablation for AF treatment. There were no exclusion criteria for this study. The primary endpoint was the occurrence of OF following catheter ablation for AF or AT treatment. The secondary endpoints were the diagnosis and management of OF as well as outcome and mortality.

Data management

Data were retrospectively and electronically collected. The analysis was performed using anonymized data only. The described data were retrospective data derived from the clinical routine of the participating centres, including routine follow-up visits. All the members of the research team were obliged to secrecy. All data were protected from unauthorized external access, as only members of the research team were permitted and enabled access to these data.

Statistical analysis

All categorical variables were reported as absolute and relative frequencies and were compared using Fisher’s exact test or the $\chi^2$ test. Continuous variables were tested for normal distribution using the Shapiro–Wilk test. They were reported as mean ± standard deviation (SD) in the case of normal distribution, otherwise as median and interquartile range (first quartile, third quartile). Continuous variables were compared using the non-paired Student’s $t$-test when normally distributed and the corresponding non-parametric test (Mann–Whitney U test) otherwise.

The association between different parameters and death was assessed using binary logistic regression and is reported as odds ratio (OR) and 95% confidence intervals (CIs).

Variables with a $P$-value <0.1 in the univariable model and considered clinically important for the outcome were included in a multivariable binary logistic regression model.

All parameters with perfect collinearity were excluded from the logistic regression analysis and were reported descriptively. The variables eligible for multivariable logistic regression are as follows: age, structural heart disease, left ventricular ejection fraction, coronary artery disease, congestive heart failure, duration of hospitalization, use of conscious sedation, use of thermal probe, anatomical PVI, and diagnostic method [computed tomography (CT), septic shock, coma, cardiac arrest, oesophageal surgery, direct oesophageal surgery without endoscopic treatment, conservative treatment]. All $P$-values are two sided. A $P$-value of <0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 28.0 (IBM SPSS Statistics).

Results

Patients’ population

A total of 609 experienced electrophysiological centres around the world were invited to participate in this study (Figure 1). Data on overall conducted AF or AT catheter ablation procedures were obtained from 214 (35%) centres in 35 countries across 5 continents. The full list of centres included in this study is available in the supplementary data (see Supplementary data online, Table S1). A total of 553 729 patients underwent catheter ablation procedures for AF or AT treatment between 1996 and 2022. The mean percentage of energy source was RF in 62.9% ± 29.8%, cryoballoon in 36.2% ± 30%, laserballoon in 0.6% ± 3%, and others in 0.3% ± 1.3%. A total of 138 patients (0.025%) from 78 centres (21 countries) experienced post-procedural OF (Figure 2).

The incidence of OF was 0.038%, while for cryoballoon it was 0.0015% ($P < 0.0001$). For other modalities, the incidence was 0.02%.

Peri-procedural data, management, and outcomes were available for 118 patients (18 countries), while relevant data were not available for 20 patients (14.5%). The final diagnoses were atrio-OF in 113/118 (95.8%) patients, oesophageo-pericardial fistula in 4/118 (3.4%) patients, and oesophageal perforation in 1 (0.8%) patient. The baseline characteristics are shown in Table 1. Forty-seven percent were female, with a mean age of 62.0 ± 11.4 years. A history of oesogastric pathology was reported in 8% of the patients, and 23% reported a pre-procedural proton pump inhibitor therapy.

The highest amount of OF per centre was five in one centre. The maximum incidence of OF at the specified time was 0.4%, whereas the minimum incidence per study centre was 0.0066% ($P < 0.01$).

Peri-procedural characteristics

Procedural data are presented in Table 2. In 114/118 patients (96.6%), the catheter ablation energy source was RF; contact force measuring catheters were used in 46% of them. The median RF power when ablating at the posterior wall was 30 (interquartile range: 25, 30) W. Besides PVI, additional left atrial (LA) lines were deployed in 45.5% of RF patients. Ablation of a roof line was performed in 30.9%, a posterior line was performed in 24.5%, and ablation of complex fractionated atrial electrograms at the posterior wall was performed in 15.2% of patients.

In 3/118 patients (2.5%), a cryoballoon ($n = 1$: first generation, Arctic Front cryoballoon, Medtronic Inc. and $n = 2$: second generation Arctic Front Advanced cryoballoon, Medtronic Inc.) was used for PVI. The minimal reported temperature was −69°C during cryoballoon application to the RIPv. No oesophageal temperature probe was utilized in any of the cryoballoon OF cases. In 1/118 patients (0.8%), the laserballoon ablation (HeartLight, Cardiofocus) was used. The maximal laser energy at the posterior wall was reported to be 10 W, and the maximal oesophageal temperature as measured via an oesophageal temperature probe was reported to be 37.1°C. An oesophageal temperature probe was utilized in 24.6% of the total OF population, and data concerning the oesophageal temperature were available for 15.3% of patients. The mean maximum measured temperature was 40.2° ± 2.2°C. A total of 74.6% reported post-procedural proton pump inhibitor therapy.

Patient presentation

The findings on patients’ presentation, diagnostic modality, and complications are depicted in Figure 3. The median time between the procedure...
and earliest onset of symptoms was 18 (7.75, 25) days (range: 0–60 days), and the median time between the procedure and OF diagnosis was 21 (15, 29.5) days (range: 2–63 days). The median time from first symptom onset to OF diagnosis was 3 (1, 9) days (range: 0–42 days). One OF occurred on Day 2 (RF, non-contact force catheter, maximum of 25 W at posterior wall, PVI only). The first symptoms occurred already on Day 1 (fever, neurological symptoms, multi-organ dysfunction, septic shock, and death before interventional or surgical treatment). Two further OF were diagnosed on Day 4 and two OF on Day 5. All early diagnosed patients reported symptoms (fever and neurological symptoms).

Figure 1 Flowchart of the POTTER-AF study. AF, atrial fibrillation; OF, oesophageal fistula; CT, computed tomography.

Figure 2 (A) Endoscopic view of the oesophagus in a patient with an atrio-oesophageal fistula. (B) Intraoperative situ during oesophageal surgery in a patient with an atrio-oesophageal fistula.
In patients treated with endoscopy alone, oesophageal surgery, or conservative treatment, the median time between the procedure and the earliest onset of symptoms was 10 (6, 15), 18 (11, 22.5) and 20.5 (10, 29) days, respectively ($P$ = 0.03). The median times between the procedure and OF diagnosis were 18 (10, 25), 21 (15, 29) and 26.5 (19, 32) days, respectively ($P$ = 0.03).

The primary initial symptoms were fever ($n$ = 70, 59.3%), chest pain or odynophagia ($n$ = 64, 54.2%), and neurological symptoms (stroke or seizures) ($n$ = 52, 44.1%). Other symptoms were reported in 74 patients (62.3%: dyspnoea, nausea, syncope, cough, AF, haematemesis, confusion, vomiting, ST-elevation myocardial infarction, and aphasia). The symptoms occurred either in isolation or in association with one another. In one patient (0.8%), no symptoms were reported.

Diagnosis was made by routine endoscopy on Day 10. In this case, a RF contact force measuring catheter with a maximum of 48 W at the posterior wall during deployment of a posterior line was utilized. After endoscopic treatment via clipping, no sequelae was reported.

The diagnosis was established by chest CT in 93 (80.2%) patients, with cerebral CT or cerebral magnetic resonance imaging in 40 (34.5%), with echocardiography in 29 (25%), with endoscopy in 24 (20.7%) patients, and other, in 20 (17.2%, autopsy, peri-cardiocentesis, lumbar puncture, cardiac surgery) of patients. Diagnosis was established using either an isolated modality or a combination of several modalities.

### Clinical course, management, and outcome
During the clinical course, delayed complications were stroke or cerebral haemorrhages (25/107, 23.4%), severe sepsis or septic shock (62/107, 57.9%), coma (50/107, 46.7%), cardiac arrest (20/107, 18.7%), gastrointestinal bleeding (18/107, 16.8%), cardiac tamponade (12/107, 11.2%), or others in 31/107 (29%). A total of 5/107 (4.7%) patients reported no complications. In two of those patients, the OF was detected during routine endoscopic ultrasound assessment and was treated by endoscopic clipping and endoscopic stenting with no and minor sequelae, respectively. In one patient, a CT scan was performed due to confusion. After detection of an OF, the patient was treated with endoscopic stenting followed by oesophageal surgery with minor long-term sequelae. Gastric liquid pericardial effusion was detected in two patients; both treated with oesophageal surgery and did not report any sequelae.

All patients were treated with intravenous antibiotic therapy. Among 116 patients diagnosed with OF, and treatment data available, $n$ = 38 (32.8%) were treated conservatively, without endoscopic of surgical...
treatment attempts, and \( n = 34 \) (89.5\%) of them died during follow-up. One patient (2.6\%) had severe sequelae, and three (7.9\%) reported no long-term sequelae.

A total of 31 (26.7\%) patients were initially treated with endoscopic therapy (oesophageal stenting (\( n = 28 \)), clipping (\( n = 2 \)), or vacuum-assisted-closure therapy (\( n = 1 \)). Due to their critical condition, 17/31 (54.8\%) died or had severe sequelae (3/31, 9.7\%). Minor sequelae were reported in 4/31 (12.9\%) patients, while 7/31 (22.6\%) had no sequelae. The oesophageal stent was removed in 4/31 (12.9\%) patients after 30–75 days.

Isolated endoscopic therapy was performed in 23 (19.8\%) patients (mortality: 13/23, 56.5\%), whereas in eight patients the initial endoscopic therapy was switched to a surgical approach due to limited benefit (mortality: 4/8, 50%).

A total of 55/116 (47.4\%) patients were treated using an oesophageal surgical approach. In one patient treated with oesophageal surgery, the data concerning mortality were not available. A total of 28/54 (51.9\%) patients treated surgically died. A direct surgical approach without a previous endoscopic treatment attempt was conducted in 47/116 (40.5\%) patients. In this group, 24/46 (52.2\%) died. In terms of mortality, there were no significant differences between patients who underwent a direct surgical approach and those who underwent a direct endoscopic approach (\( P = 0.801 \)). The overall mortality was 77/117 (65.8\%), 11/117 (9.4\%), and 11/117 (9.4\%) experienced long-term major and minor sequelae, respectively. Only 18/117 (15.4\%) reported no long-term sequelae. The mortality following surgical (51.9\%) or endoscopic treatment (56.5\%) was significantly lower than that following conservative management (89.5\%) [OR 7.463 (2.414, 23.072) \( P < 0.001 \)] (Figure 4). The median time to death was 28.5 days (19.3, 42).

In order to better understand the differences between patients receiving conservative treatment and those receiving surgical/endoscopic

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Procedural data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
<td>All patients</td>
</tr>
<tr>
<td>Usage of general anaesthesia</td>
<td>56 (47.5)</td>
</tr>
<tr>
<td>Usage of deep analgesedation</td>
<td>35 (29.7)</td>
</tr>
<tr>
<td>Procedure time, min</td>
<td>147 (108, 180)</td>
</tr>
<tr>
<td>RF energy</td>
<td>114 (96.6)</td>
</tr>
<tr>
<td>RF duration, min</td>
<td>38.5 (23.8, 52.6)</td>
</tr>
<tr>
<td>RF contact force catheter</td>
<td>52/113 (46.0)</td>
</tr>
<tr>
<td>RF power on LA posterior wall, Watts</td>
<td>30 (25, 30)</td>
</tr>
<tr>
<td>Circumferential PVI</td>
<td>102/109 (93.6)</td>
</tr>
<tr>
<td>Segmental ostial</td>
<td>2/109 (1.8)</td>
</tr>
<tr>
<td>Anatomical ostial</td>
<td>6/109 (5.5)</td>
</tr>
<tr>
<td>Additional LA line ablation</td>
<td>50/110 (45.5%)</td>
</tr>
<tr>
<td>Roof line</td>
<td>34/110 (30.9)</td>
</tr>
<tr>
<td>Posterior line</td>
<td>27/110 (24.5)</td>
</tr>
<tr>
<td>Anterior lines</td>
<td>8/110 (7.3)</td>
</tr>
<tr>
<td>Inferior lines</td>
<td>2/110 (1.8)</td>
</tr>
<tr>
<td>Mitral isthmus line</td>
<td>4/110 (3.6)</td>
</tr>
<tr>
<td>CFAE ablation at the LA posterior wall</td>
<td>12/79 (15.2)</td>
</tr>
<tr>
<td>Cryoballoon</td>
<td>3 (2.5)</td>
</tr>
<tr>
<td>1st generation cryoballoon</td>
<td>1/3 (33.3)</td>
</tr>
<tr>
<td>2nd generation cryoballoon</td>
<td>2/3 (66.6)</td>
</tr>
<tr>
<td>Range minimal temperature, C(^\circ)</td>
<td>–69—47</td>
</tr>
<tr>
<td>Laserballoon</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Maximal laser energy, Watts</td>
<td>10</td>
</tr>
<tr>
<td>Usage of oesophageal temperature probe</td>
<td>29 (24.6)</td>
</tr>
<tr>
<td>Maximal temperature, C(^\circ)</td>
<td>40.2 ± 2.2</td>
</tr>
<tr>
<td>Post-procedure prescription of PPI</td>
<td>85/114 (74.6)</td>
</tr>
</tbody>
</table>

Values are counts, \( n \) (%), mean ± SD, or median (first quartile, third quartile).

CFAE, complex fractionated atrial electrograms; LA, left atrium; PVI, pulmonary vein isolation; PPI, proton pump inhibitors; RF, radiofrequency.
treatment, the comparison between the two populations in terms of baseline characteristics, procedural data, complications, and survival was performed (see Supplementary data online, Table S4). It is important to note that the patients receiving conservative treatment had a longer time to initial symptoms [20.5 (10, 29.8) vs. 15 (6, 21.8) days; \( P = 0.037 \)] and a longer time until OF diagnosis [26 (18, 33.5) vs. 19 (13, 28.5) days; \( P = 0.019 \)], as compared to those receiving surgical/endoscopic treatment. Moreover, the patients receiving invasive treatment were more likely to be diagnosed by means of chest CT (86.8% vs. 65.8%; \( P = 0.013 \)) and less likely to be diagnosed by other methods. In terms of complications, the patients receiving surgical/endoscopic treatment were less likely to have a diagnosis of stroke during the clinical course as compared to those treated conservatively (14.7% vs. 39.5%; \( P = 0.008 \)).
Subgroup analysis of survivors vs. non-survivors

A detailed comparison of survivors and non-survivors is shown in Supplementary data online, Table S2. Concerning baseline characteristics, atrio-OF, older age, reduced left ventricular ejection fraction, and coronary artery disease showed significantly higher values in terms of mortality, while an oesophageal-pericardial fistula (n = 4 patients, 100% survival) showed a significantly lower mortality. An anterior line showed significantly higher mortality. The occurrence of septic shock, coma, cardiac arrest, and gastrointestinal bleeding was significantly higher in the non-survivors, while the rate of patients with no complications was significantly higher in the survivors. Patients with any interventional or surgical treatment, patients with oesophageal surgery as well as patients with direct oesophageal surgery without previous stenting or clipping showed a significantly lower mortality.

To identify mortality associated factors, a simple (univariable) binary logistic regression was performed (see Supplementary data online, Table S3). For identified factors with a P-value of <0.1 and considered of clinical importance for the prognosis, a multivariable binary logistic regression was conducted.

Although not significant, yet a trend towards a lower mortality was observed for the use of an oesophageal probe (OR: 0.449, P = 0.068) in the univariable logistic regression. After including this variable in the multivariable model, it was significantly associated with lower mortality (OR: 0.231, P = 0.012). Moreover, the use of conscious sedation and the treatment via oesophageal surgery were associated with better survival (Table 3).

Discussion

OF represents a rare but dreadful complication of AF catheter ablation. The incidence varies between different studies; however, it may be underreported and the true incidence is unknown. This fearful complication is associated with a very high mortality rate.2,3 Due to the limited number of cases, data concerning the incidence, management, and outcome of OF are sparse. Therefore, this complication requires an international worldwide effort to allow for a better understanding of the factors contributing to its occurrence and the optimal management strategies. To address these issues, the POTTER-AF study was conducted.

The major findings were: (i) the incidence of OF after catheter ablation for AF/AT treatment was 0.025% with an incidence of 0.038% for RF and 0.0015% for Cryoballoon (P < 0.0001); (ii) the median time to symptoms [18 (7.75, 25) days], and the median time to diagnosis [21 (15, 29.5) days] occurred relatively later after the procedure, while the median time from first symptom onset to OF diagnosis was 3 (1, 9) days (range: 0–42 days); (iii) the most common initial symptom was fever (59.3%); (iv) the diagnosis was established using chest CT in 80.2%; (v) oesophageal surgery was performed in 47.4% and a direct endoscopic treatment was conducted in 19.8%, and conservative treatment was conducted in 32.8% of cases; (vi) the overall mortality was 65.8%, 18.8% experienced long term sequelae; (vii) mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared with conservative management (89.5%) (P < 0.001); and (viii) the multivariable binary logistic regression found the conscious sedation and the use of thermal probe, as well as the treatment by means of oesophageal surgery as significantly associated with a better prognosis in terms of survival (Structured Graphical Abstract).

This worldwide survey provides the largest dataset on OF today. It reports important data to allow a better understanding of the incidence, management, and outcomes of OF occurring after AF/AT ablation. With 0.025%, the incidence of OF is in line with recent literature of a nationwide survey from France (incidence of 0.026%), which was calculated from 33 OF in 129,286 AF/AT ablations procedures.5 Other surveys with limited patient numbers reported on incidences of between 0.016% and 0.15%.2,7,16

Impact of the energy source in oesophageal fistula formation

Although OF has been mainly reported for RF based catheter ablation procedures, the latest findings suggest that OF also may occur in cryoballoon and other balloon-based ablation procedures.10,17 The incidence of OF following cryoballoon based ablation was reported as <0.001%, which may partially reflects the frequent use of oesophageal temperature probes during cryoballoon based procedures.10 The POTTER-AF study evaluated an OF in a total of 3 patients after cryoballoon based PVI which only reflects 2.5% of the analysed population. The incidence of RF (0.038%) was significantly higher than that of cryoballoon (0.0015%, P < 0.0001). This difference might partially be explained by additional ablation of LA lines in RF patients, yet most likely not completely. With a reported cryoballoon temperature of a minimum of −69°C, which is far below the suggested minimum temperature of −60°C for the Arctic Front Advanced cryoballoon, the combination of a temperature cut-off and the utilization of an oesophageal temperature probe might prevent OF in cryoballoon procedures. In 1/118 patients (0.8%), the laserballoon ablation was used. The maximal laser energy at the posterior wall was reported to be 10 W, which is in line with the recommendations.18

Since RF is still the most common energy source for cardiac ablation procedures, and the main proportion of patients included in the POTTER-AF study suffered OF after RF-based catheter ablation. The latest observations on pulsed field ablation based catheter ablation suggested that this novel non-thermal energy source might reduce oesophageal injuries and potentially OF due to its selectivity to cardiomyocytes.19

**Table 3** Multivariable binary logistic regression

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>OR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>1.039</td>
<td>0.995–1.084</td>
<td>0.081</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>0.992</td>
<td>0.942–1.044</td>
<td>0.748</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>3.096</td>
<td>0.555–17.259</td>
<td>0.197</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>2.625</td>
<td>0.555–12.411</td>
<td>0.223</td>
</tr>
<tr>
<td>Conscious sedation</td>
<td>0.229</td>
<td>0.060–0.865</td>
<td>0.030</td>
</tr>
<tr>
<td>Use of thermal probe</td>
<td>0.231</td>
<td>0.074–0.724</td>
<td>0.012</td>
</tr>
<tr>
<td>Diagnostic CT</td>
<td>0.371</td>
<td>0.093–1.481</td>
<td>0.160</td>
</tr>
<tr>
<td>Oesophageal surgery</td>
<td>0.329</td>
<td>0.123–0.881</td>
<td>0.027</td>
</tr>
</tbody>
</table>

The continuous variables have the unit of measurement in brackets. All other variables are categorical variables.

CI, confidence interval; CT, computed tomography; OR, odds ratio; LVEF, left ventricular ejection fraction.
Prevention of oesophageal fistula

Utilization of oesophageal temperature probes is a common strategy to monitor the oesophageal temperature and potentially prevent oesophageal injuries. While for cryoballoon and laserballoon-based ablation, the use of an oesophageal temperature probe is a commonly accepted strategy. However, its usage during RF based ablation is less common, and one study showed that it could be a risk factor for the development of endoscopically detected esophageal lesions. However, in general, the use of a temperature probe seems to be a potential way to reduce the risk of oesophageal overheating and cooling and therefore a potential strategy to prevent oesophageal injuries. In the POTTER-AF study, an oesophageal temperature probe was utilized in 24.6% of POTTER-AF patients, and the mean maximal measured temperature was 40.2 ± 2.2°C.

Clinical presentation and diagnostics

Although the pathophysiology of OF development is not completely understood, there is agreement that ablation energy from any source delivered to the posterior LA wall leads to thermal damage to the oesophagus. Since lesion formation requires time to progress, the first symptoms typically occur within 60 days after the procedure. The symptoms are diverse and not specific, consisting primarily of fever and neurological abnormalities, sometimes mimicking a cerebral vascular accident. The findings of POTTER-AF are in line with these observations since most patients reported fever (59.3%), chest pain/odynophagia (54.2%), and neurological signs (44.1%). With a median of 18 (7.75, 25) days (range 0–60), the observed time to symptoms was shorter than previously reported. Additionally, the time to diagnosis [median 21 (15, 29.5) days, range: 2–63 days] and time from first symptom onset to OF diagnosis [3 (1, 9) days (range: 0–42 days)] were relatively short but showed a relatively wide range. This observation might reflect the possibility that some patients presented at hospitals where they had not received the catheter ablation procedure which might lead to a longer time to diagnosis compared to the patients who presented at experienced electrophysiological centres who are potentially more aware of OF. In order to plan rapid treatment of OF, it is essential to detect this complication early. In more than 80% of patients, a chest CT was the most common diagnostic method, which has been previously recommended by other authors. In the CT scan, signs such as oesophageal opacification and air detected inside the left atrium are highly suggested to be associated with OF. It is important to state that endoscopy is discouraged that air should not be injected into the oesophagus due to the potential development of air embolism.

Treatment strategies and outcome

Since most patients reported fever and developed sepsis and/or septic shock, all patients were treated with antibiotics. The overall mortality was 65.8%, with significantly reduced mortality in patients undergoing surgical repair (51.9%) compared with endoscopic treatment only (56.5%) and conservative management (89.5%) [OR 7.463 (2.414, 23.072) P < 0.001], compared with conservative treatment.

Although these observed improvements in mortality are highly significant, the reason for the different treatment strategies shows a selection bias, since patients who were not able to undergo any oesophageal surgery or endoscopic treatment and received conservative treatment due to critical illness had the worst outcome. In fact, the time to the earliest onset of symptoms and the time to OF diagnosis were the shortest in patients who received endoscopic treatment only followed by oesophageal surgery and conservative treatment. Patients with an early OF detection received an early treatment via endoscopy or oesophageal surgery with a lower mortality while patients with late detection more often received a conservative treatment with a higher mortality. This observation again underlines the importance of early diagnosis, detection, and treatment of OF. The findings of the multivariable binary logistic regression analysis detected an intervention of OF patients via an oesophageal surgery as a factor that was associated with a lower mortality. Coronary artery disease, coma, and cardiac arrest were identified as the factors associated with a higher mortality. The use of an oesophageal thermal probe and the use of conscious sedation were also associated with better survival.

These observations are in line with a large meta-analysis conducted in 2017 with 120 reported OF cases from a total of 85 studies. The overall mortality was reported to be 55%, with significantly reduced mortality in patients undergoing surgical repair (33%) compared to endoscopic treatment (65%) and conservative management (97%).

Limitations

The POTTER-AF study has several limitations. First, the findings were based on a retrospective analysis. Nevertheless, the data were obtained from a large number of centres across the globe represent the largest database on OF up to date. Second, since only data from patients with peri-procedural OF were collected, we were unable to assess predictors of its occurrence. Third, not all data were available and some patients were lost to follow-up. Fourth, because OF typically occurs relatively late after the procedure, the incidence may be underestimated, and the true incidence remains unknown. Fifth, there were no data on how the temperature measured by the oesophageal temperature probe was utilized in these patients, and no cut-off values were available. Sixth, no accurate data were available reporting on the specific ablation design for the participating centres. Seventh, no subgroup analysis on the incidence of the use of contact force catheters, ablation index, and lesion size index was available. Eighth, the absence of data from a significant proportion of invited centres strongly limits the applicability of the present results to a general population and may result in underestimation of the true incidence of OF. Finally, our findings concerning different treatment strategies and outcomes show the above-mentioned selection bias concerning critical illness and operability of the patients.

Conclusions

In this large worldwide registry, the incidence of OF was very low; in general, the incidence was lower for cryoballoon- compared to RF-based procedures. The observed time to symptoms was shorter than previously reported. Additionally, the time to diagnosis and the time from first symptom onset to OF diagnosis were relatively short but showed a relatively wide range. The overall prognosis was poor. Surgical or endoscopic intervention is mandatory for improving patient survival.

Acknowledgements

We thank all the local investigators and assistant personnel for their great effort. Furthermore, we thank all the POTTER-AF collaborators listed in the Supplementary data online, Table S2.

Supplementary data

Supplementary data is available at European Heart Journal online.
Pre-registered clinical trial number
The pre-registered clinical trial number is ClinicalTrials.gov Identifier: NCT05273645.

Ethical approval
The registry was approved by the local ethical review board of the University of Lübeck, Germany (AZ 21–291). Each participating centre was responsible for its ethics approval by the local ethics committee. The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. All patient information was anonymized.

Data availability
Non-digital data supporting this study are curated at the Study Center of the Department of Rhythmology, University Hospital Schleswig-Holstein, Germany.

Conflict of interest
R.R.T. is a consultant for Boston Scientific, Biotronik, and Biosense Webster and received speaker honoraria from Biosense Webster, Medtronic, Boston Scientific, and Abbott Medical. K.-H.K. reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster, outside the submitted work. C.H.H. received travel grants and research grants from Boston Scientific, Lifetech, Biosense Webster, and Cardiofocus and speaker honoraria from Medtronic, Boston Scientific, Biosense Webster, Cardiofocus and C.T.I. GmbH and Doctrina Med. He is a consultant of Boston Scientific, Lifetech, Biosense Webster, and Cardiofocus. H.P.—receipt of honoraria or consultation fees: Bayer, Daiichi-Sankyo, Boehringer-Ingelheim, Pfizer, Abbott, Biosense-Webster, Boston Scientific, and Medtronic; participation in a company sponsored speaker’s bureau: Biosense Webster, Abbott, Medtronic, Boston. M.M.—consultant and speaker: Abbott Medical, Biosense Webster, Medtronic, and Boston Scientific. P.S.—advisory Board for Biosense Webster, Boston Scientific, Abbott, and Medtronic. C.S. received research support and lecture fees from Medtronic, Abbott, Boston Scientific, and Biosense Webster. In addition, C.S. is a consultant for Medtronic, Boston Scientific, and Biosense Webster. C.V.—consultant fees: Abbott, Biosense Webster, Medtronic, and C.R. If on behalf of: Abbott Medical, Biosense Webster, Medtronic, and Boston Scientific. C.H.H. reported consultant fees from J. Michael S. Chauret, Inc. and Medtronic. K.H.K. received travel grants and speaker honoraria from Abbott, Boston Scientific, Biosense Webster, and Medtronic. He also reports grants from the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel, and the University of Basel. M.K. reports grants from the Swiss National Science Foundation (Grant numbers 33CS20_148474, 33CS17_177520, 32473B_176178, 32003B_197524), the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel and the University of Basel, grants from Bayer, grants from Pfizer, grants from Boston Scientific, grants from BMS, grants from Biotronik, grants and personal fees from Daiichi Sankyo. L.R. has received speaker/consulting honoraria from Abbott/SJM and from Medtronic and has received a research grant for an investigator-initiated study to the institution from Medtronic. A.M.S. received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker/advisory board/consulting fees from Bayer Healthcare, Biotronik, Daiichi-Sankyo, Medtronic, Novartis, Pfizer and Stride Bio Inc. C.G.—research grants: MicroPort CRM. Consultant: MicroPort CRM, Boston Scientific, Abbott, Medtronic. Honoria: Biotronik, Medtronic, Astra-Zeneca, BMS-Pfizer, Biosense-Webster. L.F. reports consulting fees for AstraZeneca, Bayer, BMS/Pfizer, Boehringer, Medtronic, Novo Nordisk, and Novartis and lecture fees for AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim and Zoll. S.B.—consultant for Medtronic, Boston Scientific, Micropor, and Zoll. N.L.—consulting fees for Abbott Medtronic and Boston Scientific. P.J. Grant from Biosense Webster, Metronic, ABBOTT, Boston. N.D. consultant for Biosense Webster. C.M. BSCI, Medtronic, Biosense Webster, Adagio—speaker honoraria and consultancy fees. P.H. BSCI and Medtronic—speaker honoraria. J.C. serves as a consultant for Biosense Webster, Johnson & Johnson. G.L.—In general, I have received funding from Biosense Webster, Medtronic, and Abbott (speaker honoraria). E.E.O.—payment from healthcare industry to my institution for my personal services: honoraria, consultancy, advisory board: Biosense Webster, Medtronic, H.Y.—proctor for Abbott, Medtronic, and Biosense Webster. S.C.—travel grants and speaker’s honoraria from Medtronic, Biosense Webster, and Abbott and is a proctor of Medtronic and Biotronik. E.J.—consultant fees from Biotronik, Medtronic, Abbott, Boston Scientific. K.O. received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. J.N.C. Circa Scientific research support. V.Y.R. does not report any disclosures directly related to this manuscript; but unrelated to this manuscript, he has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Anumantra, Apama, Medical-Boston Scientific, APN Health, Aquaheat, Atacor, Autonomix, Avon Therapies, Backbeat, BioSig, CardioCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinoval-Hangzhou DiNovo EP Technology, East End Medical, EP-Phils, EP Frontiers, Epix Therapeutics-Medtronic, EpIEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, Valeare; unrelated to this work, has served as a consultant for Abbott, AtriAN, Biosense-Webster, BioTel Heart, Biotronik, Boston Scientific, Cardiac, Cardiofocus, Cardionic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Novartis, Philips, Pulse Biosciences; and has equity in Manual Surgical Sciences, Newpax, Nyra Medical, Surecor, and Vizamed™. A.N. consultant for Abbott, Baylis, biosense webster, biontronik, boston scientific and Medtronic DS research grant: Abbott, Medtronic, Johnson&Johnson; advisory board: Pfizer, Abbott; speaker fee: Abbott, Medtronic, Johnson&Johnson. J.L.M. received speaker fees and/or honoraria
for lectures and scientific advice from Biotronik, Medtronic, Micropor, Milestone Pharmaceutical, Sanofi, and Zoll. K.H.K. reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster outside submitted work. All other authors have no relevant disclosures.

**Funding**

All authors declare no funding for this contribution.

**References**


Downloaded from https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad250/7123667 by guest on 30 June 2023